Bicara Therapeutics BCAX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $112M+18.0% | $94.9M+10.5% | $85.9M+35.1% | ||
| $35.8M+17.3% | $30.51M+4.7% | $29.13M+11.2% | $26.19M+14.5% | $22.88M+21.9% | ||
| $174.06M+11.9% | $155.6M+10.3% | $141.12M+16.6% | $121.07M+11.3% | $108.8M+32.1% | ||
| -$174.06M-11.9% | -$155.6M-10.3% | -$141.12M-16.6% | -$121.07M-11.3% | -$108.8M-32.1% | ||
| $16.94M-5.2% | $17.87M-10.4% | $19.95M+6.6% | $18.71M+11.8% | $16.73M+14.7% | ||
| -$157.12M-14.1% | -$137.73M-13.7% | -$121.17M-18.4% | -$102.36M-11.2% | -$92.08M-35.8% | ||
| $197K-9.2% | $217K-38.0% | $350K+12.9% | $310K+20.2% | $258K+38.0% | ||
| -$157.32M-14.0% | -$137.95M-13.5% | -$121.52M-18.4% | -$102.67M-11.2% | -$92.33M-35.8% | ||
| -$2.78-9.9% | -$2.53— | —— | —— | —— | ||
| -$173.93M-11.9% | -$155.5M-10.3% | -$141.04M-16.6% | -$121M-11.3% | -$108.74M-32.1% | ||
| -$174.06M-11.9% | -$155.6M-10.3% | -$141.12M-16.6% | -$121.07M-11.3% | -$108.8M-32.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Bicara Therapeutics's income statement data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.